Michigan hospitals are systematically exploiting a program for low-income patients, according to a new report.

Recent data released by the Health Resources and Services Administration show that drug purchases made under the 340B Drug Pricing Program totaled $81.4 billion in 2024.

A Colorado district court judge denied drug manufacturer AstraZeneca’s request for an injunction to block enforcement of a recent law barring drug manufacturers from imposing restrictions on covered ...

An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug ...

Healthcare policy changes may increase uncompensated care, stressing hospitals and the 340B program, crucial for subsidizing low-income patient care. The 340B rebate model, starting in 2026, could ...

The 340B Drug Pricing Program was meant to help low-income patients, writes Rick Dowlearn, but it’s being used by hospitals ...

As the January 1 implementation date approaches, here is a quick guide to the controversial new rebate model for the 340B Drug Pricing Program and the legal battle to stop it.

The AHA and several safety-net providers argue that an upcoming mandatory rebate pilot violates administrative law, imposes millions in costs, and threatens patient care in vulnerable communities.

California system riding outpatient wave, John Muir Health, expands infusion services and integrates pharmacists to enhance patient care and convenience.

Learn more about whether iRhythm Technologies, Inc. or Omnicell, Inc. is a better investment based on AAII's A+ Investor ...

Learn more about whether Haemonetics Corporation or Omnicell, Inc. is a better investment based on AAII's A+ Investor grades, ...